Celon Pharma at the BIO International Convention 2019

2019-05-24 | News

The Company’s representatives will participate in the BIO International Convention 2019, an international convention which attracts over 16.000 biotechnology and pharmacy leaders each year. The conference allows for networking and collaboration in the field of drug development. Maciej Wieczorek, CEO of Celon Pharma S.A.: We can confirm the growing interest in our projects in theRead more »

Welcome to Celon Pharma S.A.

Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.


FDA approved FGFR as new and validated molecular aim in cancer treatment

On 12 April 2019, the Food and Drug Administration (FDA) allowed the marketing of erdafitinib in urinary tract cancer treatment. This decision confirms the great potential of FGFR inhibitors in various solid cancers with FGFR aberrations and proves the recognition of this class medicines as new tools in advanced solid cancers treatment. Celon Pharma S.A.Read more »

Job offers

People are the key to the success of all projects. We know this well and we would also like you to learn this first hand. As a Celon Pharma S.A. employee, you will be provided with an attractive salary, in-depth training and an incentive system. What is equally important, you will have the satisfaction of working with modern and essential drugs which save and extend human life.

Read more »